Tapering of biological treatment in autoinflammatory diseases: a scoping review

Tapering of biological treatment in autoinflammatory diseases: a scoping review

Abstract Background Biological treatment and treat-to-target approaches guide the achievement of inactive disease and clinical remission in Autoinflammatory Diseases (AID). However, there is limited evidence addressing optimal tapering strategies and/or discontinuation of biological treatment in AID...

Full description

Bibliographic Details
Main Authors:	Tatjana Welzel, Lea Oefelein, Marinka Twilt, Marc Pfister, Jasmin B. Kuemmerle-Deschner, Susanne M. Benseler
Format:	Article
Language:	English
Published:	BMC 2022-08-01
Series:	Pediatric Rheumatology Online Journal
Subjects:	bDMARDs AID Treat to target Pharmacokinetics Pharmacodynamics Personalized treatment
Online Access:	https://doi.org/10.1186/s12969-022-00725-3

Similar Items

Management of Monogenic IL-1 Mediated Autoinflammatory Diseases in Childhood
by: Tatjana Welzel, et al.
Published: (2021-03-01)

The Aftermath of Tapering Tocilizumab After Achieving Treatment Target in Patients With Rheumatoid Arthritis: A Nationwide Cohort Study
by: Jun Won Park, et al.
Published: (2022-02-01)

Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis
by: Thomas Wilke, et al.
Published: (2017-08-01)

Value of Literature Review to Inform Development and Use of Biologics in Juvenile Idiopathic Arthritis
by: Klervi Golhen, et al.
Published: (2022-06-01)

Prediction Aided Tapering In rheumatoid arthritis patients treated with biOlogicals (PATIO): protocol for a randomized controlled trial
by: Marianne A. Messelink, et al.
Published: (2022-06-01)

Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry
by: Jerusalem Calvo-Gutiérrez, et al.
Published: (2024-02-01)

Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort studyResearch in context
by: Maxime Beydon, et al.
Published: (2023-12-01)

Biological treatment and exercise as an alternative to typical rheumatoid arthritis therapy: pathophysiology and effects
by: Artur Aghadi, et al.
Published: (2023-02-01)

Prediction of ineffectiveness of biological drugs using machine learning and explainable AI methods: data from the Austrian Biological Registry BioReg
by: Dubravka Ukalovic, et al.
Published: (2024-02-01)

Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review
by: Claudia Iannone, et al.
Published: (2023-02-01)

Anti-rheumatic treatment and prosthetic joint infection: an observational study in 494 elective hip and knee arthroplasties
by: Ylva Borgas, et al.
Published: (2020-06-01)

Analysis of survival rate and persistence predictors of baricitinib in real-world data from a large cohort of rheumatoid arthritis patients
by: Simone Parisi, et al.
Published: (2024-01-01)

Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment
by: Krzysztof Bonek, et al.
Published: (2021-02-01)

Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study
by: Eleni Kampylafka, et al.
Published: (2018-07-01)

Novel Therapies in Takayasu Arteritis
by: Francesca Regola, et al.
Published: (2022-01-01)

The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis
by: Rieke Alten, et al.
Published: (2022-10-01)

The efficacy of tofacitinib combined with bDMARDs in the treatment of ankylosing spondylitis patients with inadequate response to bDMARDs: a retrospective study
by: Jie Chang, et al.
Published: (2024-01-01)

Cytokine Signatures in Psoriatic Arthritis Patients Indicate Different Phenotypic Traits Comparing Responders and Non-Responders of IL-17A and TNFα Inhibitors
by: Marie Skougaard, et al.
Published: (2023-03-01)

The Role of M1/M2 Macrophage Polarization in Rheumatoid Arthritis Synovitis
by: Maurizio Cutolo, et al.
Published: (2022-05-01)

Difficult-to-treat rheumatoid arthritis in real clinical practice. Preliminary results
by: Elena A. Galushko, et al.
Published: (2022-06-01)

Using real-world data to dynamically predict flares during tapering of biological DMARDs in rheumatoid arthritis: development, validation, and potential impact of prediction-aided decisions
by: Matthijs S. van der Leeuw, et al.
Published: (2022-03-01)

Colchicine – an effective treatment for children with a clinical diagnosis of autoinflammatory diseases without pathogenic gene variants
by: Tatjana Welzel, et al.
Published: (2021-09-01)

Changes in Inflammatory Cytokines in Responders and Non-Responders to TNFα Inhibitor and IL-17A Inhibitor: A Study Examining Psoriatic Arthritis Patients
by: Marie Skougaard, et al.
Published: (2024-03-01)

Compared efficacy of rituximab, abatacept, and tocilizumab in patients with rheumatoid arthritis refractory to methotrexate or TNF inhibitors agents: a systematic review and network meta-analysis
by: Alisson Pugliesi, et al.
Published: (2023-07-01)

VZV-specific T-cell levels in patients with rheumatic diseases are reduced and differentially influenced by antirheumatic drugs
by: David Schub, et al.
Published: (2018-11-01)

Prospective study to characterize adalimumab exposure in pediatric patients with rheumatic diseases
by: Tatjana Welzel, et al.
Published: (2024-01-01)

Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region
by: Zoltán Kaló, et al.
Published: (2017-01-01)

Effect of Dysmetabolisms and Comorbidities on the Efficacy and Safety of Biological Therapy in Chronic Inflammatory Joint Diseases
by: Laura Cometi, et al.
Published: (2020-05-01)

IL-10 Induced by mTNF Crosslinking-Mediated Reverse Signaling in a Whole Blood Assay Is Predictive of Response to TNFi Therapy in Rheumatoid Arthritis
by: Marco Krasselt, et al.
Published: (2022-06-01)

The incidence of opportunistic infections in patients with psoriatic arthritis treated with biologic and targeted synthetic agents: A systematic review and meta-analysis
by: Athanasios Vassilopoulos, et al.
Published: (2022-10-01)

Stopping bDMARDs at the beginning of pregnancy is associated with disease flares and preterm delivery in women with rheumatoid arthritis
by: Maria Chiara Gerardi, et al.
Published: (2022-08-01)

Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant?
by: Santiago Rodrigues Manica, et al.
Published: (2020-08-01)

Impact of access to treatment on patient‐reported outcomes among rheumatoid arthritis patients with tDMARDs and bDMARDS in two Latin‐American countries: A prospective observational study
by: Juan M. Reyes, et al.
Published: (2023-03-01)

Influence of the timing of biological treatment initiation on Juvenile Idiopathic Arthritis long-term outcomes
by: Filipa Oliveira Ramos, et al.
Published: (2023-09-01)

Biologic Disease-Modifying Antirheumatic Drugs for Preventing Radiographic Progression in Psoriatic Arthritis: A Systematic Review and Network Meta-Analysis
by: Szu-Hsuan Wang, et al.
Published: (2022-10-01)

Ultrasound-detected bone erosion is a relapse risk factor after discontinuation of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis whose ultrasound power Doppler synovitis activity and clinical disease activity are well controlled
by: Shin-ya Kawashiri, et al.
Published: (2017-05-01)

The accelerated waning of immunity and reduced effect of booster in patients treated with bDMARD and tsDMARD after SARS-CoV-2 mRNA vaccination
by: Selma Tobudic, et al.
Published: (2023-02-01)

Consensus protocols for the diagnosis and management of the hereditary autoinflammatory syndromes CAPS, TRAPS and MKD/HIDS: a German PRO-KIND initiative
by: Sandra Hansmann, et al.
Published: (2020-02-01)

Pharmacokinetic targets of antiretroviral therapy in children and adolescents
by: Michael N. Neely, et al.
Published: (2013-10-01)

The pharmacological and clinical aspects behind dose loading of biological disease modifying anti-rheumatic drugs (bDMARDs) in auto-immune rheumatic diseases (AIRDs): rationale and systematic narrative review of clinical evidence
by: Gerlienke E. Geurts-Voerman, et al.
Published: (2020-07-01)